drugset

drugset / Trial / NCT04603924

Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients

NCT04603924 ↗

Phase 2/3 Completed 49 enrolled NeuroBo Pharmaceuticals Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Study of ANA001 in Moderate and Severe COVID-19 Patients

Timeline

Start: 2020-10-07
Primary completion: 2022-02-16
Completion: 2022-02-16

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Niclosamide	Unknown	1000 mg	Oral

Indications